Skip to Content

Coca-Cola’s ‘Stellar’ Q2 Earnings Highlights Strength of Beverage Portfolio

Coke’s stock trading above $58 fair value estimate as long-term view unchanged.

Coca-Cola logo bottle cap
Securities In This Article
Coca-Cola Co
(KO)

We think Coca-Cola’s (KO) stellar second-quarter results showcased the pricing power of its stout beverage portfolio. Organic revenue growth clocked in at 16% (12% from price/mix and 4% from concentrate sales), on top of whopping 37% organic revenue growth in the same period a year ago. And even as prices at the shelf have continued to climb (including roughly 8%-10% inflation rate in the U.S. and Europe, per management), demand elasticities remain resilient, further evidence of Coke’s strong brand intangible asset. From our vantage point, the extent to which Coke is prioritizing innovation at the premium and value tier (particularly as it relates to varying pack sizes) should help stymie the threat of ongoing inflationary pressures to volumes.

Profits shriveled, however, with the adjusted operating margin slipping roughly 110 basis points to 30.7%, due to a slew of factors (the consolidation of BodyArmor finished goods business and currency headwinds, latter of which should prove transitory, in our view). While management expects higher commodity costs to persist in the back half of the year, we believe Coke is well-equipped with the necessary arsenal to combat these pressures. We particularly view price/pack architecture and incidence-based pricing strategies as prudent and believe further cost savings should dull the hit to profits longer term, with our forecast calling for operating margins in the low-30s by 2026.

In concert with these second-quarter marks, management edged up its fiscal 2022 top-line guidance, now expecting 12%-13% organic sales growth (from 7%-8% prior), while holding firm on its comparable adjusted EPS growth of 5%-6% (From $2.32 in 2021). We may adjust our near-term forecast to reflect the results through the first half of the year, but our long-term outlook (which includes mid-single-digit top-line growth) stays intact. Shares trade above our unchanged $58 fair value estimate, and we suggest investors await a more compelling risk/reward.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

About the Author

Erin Lash

Sector Director
More from Author

Erin Lash, CFA, is director of consumer sector equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. In addition to leading the sector team, Lash covers packaged food and household and personal care companies.

Before joining Morningstar in 2006, she spent four years as an investment analyst covering retail, transportation, and technology firms for State Farm Insurance.

Lash holds a bachelor’s degree in finance from Bradley University and a master’s degree in business administration, with concentrations in accounting and finance, from the University of Chicago Booth School of Business. She also holds the Chartered Financial Analyst® designation. She ranked second in the food and tobacco industry in The Wall Street Journal’s annual “Best on the Street” analysts survey in 2013, the last year the survey was conducted.

Sponsor Center